Logo

Sirius Therapeutics Commences P-I Study of SRSD107 for Treating Thromboembolic Disorders

Share this
Sirius Therapeutics

Sirius Therapeutics Commences P-I Study of SRSD107 for Treating Thromboembolic Disorders

Shots:

  • Sirius Therapeutics has dosed the first participant with SRSD107 in the P-I, FIH, study on Jan 30, 2024
  • The P-I trial investigates the safety, tolerability and PK/PD of SRSD107 at single ascending doses and multiple ascending doses among healthy individuals in Australia
  • SRSD107 is a double-stranded siRNA targeting coagulation factor XI mRNA to inhibit FXI protein expression blocking the intrinsic coagulation pathway thus promoting anticoagulant and anti-thrombotic effects

Ref: Sirius Therapeutics | Image: Sirius Therapeutics 

Related News:- GSK Reports the NMPA Acceptance of NDA for Nucala (mepolizumab) to Treat Severe Eosinophilic Asthma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions